Renal Denervation Results Promising
Treatment shown to benefit patients with stage 3 or 4 CKD and treatment-resistant hypertension.
Treatment shown to benefit patients with stage 3 or 4 CKD and treatment-resistant hypertension.
Absence of a link found in a pooled analysis of two trials with a total of about 8,600 participants.
The two conditions together are associated with a 20-fold increased risk of atrial fibrillation.
Halving the dosage improved GFR in patients with stable heart failure and impaired renal function.
Both approaches are associated with similar outcomes in patients with renal artery stenosis and CKD or hypertension.
Patients with both heart disease and CKD experience decreased risk of cardiovascular events.
Researchers find no difference between saline and sodium bicarbonate.
ATLANTA—The goal systolic blood pressure (SBP) of less than 130 mm Hg for patients with diabetes should be reconsidered.
NEW ORLEANS—Most heart failure patients with renal failure can be managed successfully with ACE inhibitors or angiotensin receptor blockers (ARBs), and the treatment is associated with better outcomes, said Virgina B. Thayer, MS, at the 2008 scientific sessions of the American Heart Association.
NEW ORLEANS—MI patients who have CKD are less likely to receive evidence-based therapies for MI and are more likely to die than those without CKD, Stephen D. Wiviott, MD, said at the 2008 scientific sessions of the American Heart Association.